Thermo Fisher Scientific (TMO) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Thermo Fisher is expected to report Q3 2026 results on October 21, with analysts forecasting $6.40 in EPS and $11.95 billion in revenue. The company’s full-year EPS guidance is $24.930–$25.330.
• The company’s previous quarter exceeded expectations, delivering $6.03 EPS versus a $5.71 consensus and $11.99 billion in revenue, up 10.5% year over year. Analysts cite improving biotech and pharmaceutical demand as support for continued growth.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and recent price-target increases, although shares appear near fair value and insiders have sold roughly $44.1 million of stock over the past three months.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect Thermo Fisher Scientific to announce earnings of $6.40 per share and revenue of $11.95 billion for the quarter. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 7:00 AM ET.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 earnings per share. On average, analysts expect Thermo Fisher Scientific to post $25.13 EPS for the current fiscal year and $27.52 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $663.46 on Wednesday. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $694.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a 50 day moving average price of $631.12 and a two-hundred day moving average price of $544.23. The firm has a market capitalization of $245.32 billion, a P/E ratio of 35.69, a P/E/G ratio of 2.77 and a beta of 0.87.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Improving end-market demand: A Lindsell Train investor letter highlighted a rebound in biotech and pharmaceutical activity that is supporting Thermo Fisher’s organic growth, particularly across bioproduction and related services. Biotech and Pharma Rebound Strengthen Thermo’s Organic Growth
• Positive Sentiment: Upward earnings revision: Erste Group raised its FY2027 EPS forecast for TMO to $27.51 from $27.44, reinforcing expectations for continued earnings growth above the current-year consensus estimate of $25.13. Thermo Fisher analyst estimate update
• Positive Sentiment: Buy-rating upgrade: Zacks upgraded Thermo Fisher to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade can support investor confidence ahead of the company’s results. Thermo Fisher rating upgrade to Buy
• Positive Sentiment: Positive Q3 setup: Analysts expect revenue and EPS growth when Thermo Fisher reports third-quarter results, supported by bioproduction demand, product innovation and strength in clinical research. Thermo Fisher Q3 earnings preview
• Neutral Sentiment: Broader drug-development role: Thermo Fisher is expanding its involvement across clinical trials, drug manufacturing and evidence generation, including a Phase 2 multiple sclerosis program for Quantum BioPharma. The initiatives strengthen its long-term positioning but are not expected to immediately change earnings. Thermo Fisher expanded drug lifecycle role
• Negative Sentiment: Valuation remains a consideration: After a substantial multiyear advance, an analysis suggested TMO is trading near fair value based on expected cash generation. That could make additional gains increasingly dependent on earnings beats or stronger guidance. Thermo Fisher trades near fair value

Analysts Set New Price Targets

A number of research firms recently weighed in on TMO. UBS Group raised shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and raised their price target for the company from $540.00 to $730.00 in a research report on Tuesday, September 8th. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the stock a "buy" rating in a research report on Tuesday. Jefferies Financial Group reiterated a "buy" rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. BMO Capital Markets cut shares of Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday, September 9th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $642.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.